Current Market Information

Last Trade Price (LTP) 52.50 Last Trade Date 30 April, 2025 Change 1.94 % Open Price 51.50 Day's Range 52.50 - 52.50     Total Trade 1 Total Volume 500 Close Price 0 Yesterday Close Price 51.50 Market Capital in BDT (mn) 5531.935

Contact Information

Designation Name Mobile Number Email Chairman Professor Dr. Sarder A. Nayeem MD Dr. Sayeed Ahmed CFO Mr. Hassan Shahid Sarwar FCA Company Secretary Mr. Lorens Shamol Mollick FCS 01321131222 secretary@navanapharma.com Office Address Plot 99, Road 04, Block B, Banani, Dhaka 1213 Phone : 02-55033580-3 Fax : 02-55033579 Email : cs@navanapharma.com Website : http://www.navanapharma.com Factory Address Rupshi, Rupganj, Narayanganj

Basic Information

Authorized Capital in BDT* (mn) 2,000.00 Paid-up Capital in BDT* (mn) 1,074.16 Face Value 10 Paid up Share 107416217     Market Lot 1 Sector PHARMA & CHEMICALS Market Category A

Other Information

Listing Year 2022 Debut Trade Date 18 October, 2022 Type of Instrument Equity     52 Week's Range 39.50 - 114.40 Year End 30 June Reserve / Surplus(mn) 3038.76 Remarks Tk. 1,848,295,335 Revaluation Reserve has been added to Reserve & Surplus. Note

Share Holding Percentage

Sponsor/Director Govt. Institute Foreign Public As on 31-Mar, 2025 31.69 0 8.21 19.64 40.46 As on 28-Feb, 2025 31.69 0 8.28 19.64 40.39 As on 31-Jan, 2025 31.69 0 7.88 19.64 40.79 As on 30-Jun, 2024 (year ended) 35.49 0 9.22 27.73 27.56     Remarks Note     Credit Rating Status Credit Rating Year Long Term Short Term Outlook Validity Date Credit Rating Company Dec 02, 2024 AA ST-2 Stable Dec 01, 2025 National Credit Rating Ltd. Aug 01, 2023 AA ST-2 Stable Jul 31, 2024 National Credit Rating Ltd. May 12, 2022 AA ST-2 Stable May 11, 2023 National Credit Rating Ltd.         Half Year End (HY) Information  202412 HY Net Turnover(mn)  4363.72 HY Net Profit after tax(mn)  241.44 HY EPS  2.25  AGM Information   AGM Date  31 December, 2024 Record Date  19 November, 2024 Dividend(%)  14.00 (Cash only for General Shareholders (Sponsor shareholders and Directors and few shareholders who hold significant share of the company will not receive any dividend-June 2024) Bonus Issue

   

Financial Performance
Performance Year	Basic EPS Based On		Basic EPS (restated) Based On		Net Asset Value Per Share	Restated Net Asset Value Per Share	Net Profit After Tax(mn)		% Dividend	% Dividend Yield
	Continuous operations	Including Extra-Ordinary Income	Continuous operations	Including Extra-Ordinary Income			Continuous operations	Including Extra-Ordinary Income
2024	3.77	0	0	0	42.46	0	404.63	0	14%C	1.59
2023	3.59	0	0	0	40.71	0	356.94	0	13%C	1.11
2022	3.42	0	0	0	43.41	0	274	0	11%C	0
2021	2.52	0	1.88	0	41.19	37.74	202.29	0		0

Financial Statements
Quarterly Financial Statement	https://navanapharma.com/page/quarterly-accounts
Price Sensitive Information	https://navanapharma.com/page/psi

Close Price and Traded Volume Graph
Click here to view 1 month graph	Click here to view 3 month graph	Click here to view 6 month graph
Form	To